MedTrace Logo

Probability of OncotypeDx to Reallocate As Low or High Risk of Recurrence Breast Cancer Patients with Uncertain Biology

NCT06363812 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 258

Last updated 2025-02-28

No results posted yet for this study

Summary

In some cases of hormone receptor positive, human epidermal growth factor receptor 2 (HER2) negative early breast cancer the benefit of adding adjuvant chemotherapy to hormonal treatment, estimated on the basis of the classical clinico-pathological parameters, is unclear. In these cases the application of a genomic test could be useful in guiding the therapeutic choice.

Conditions

Sponsors & Collaborators

  • Genomic Health®, Inc.

    collaborator INDUSTRY

  • Istituto Toscano Tumori

    collaborator OTHER

  • Fondazione Sandro Pitigliani

    lead OTHER

Principal Investigators

  • Laura Biganzoli, MD · Hospital of Prato

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-08
Primary Completion
2021-05-15
Completion
2024-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06363812 on ClinicalTrials.gov